易瑞生物: 第三届董事会第十一次会议决议公告

Group 1 - The company held its 11th meeting of the 3rd Board of Directors on May 30, 2025, with all 7 directors present, ensuring compliance with legal and regulatory requirements [1][2] - The Board approved a proposal to expand the business scope to include "inspection and testing services" to meet operational needs [1][2] - As of May 29, 2025, the company's total share capital increased from 400,865,155 shares to 401,317,665 shares due to the conversion of convertible bonds, leading to a corresponding increase in registered capital [1][2] Group 2 - The proposal requires approval from the shareholders' meeting, needing a two-thirds majority of the voting rights present [2] - The company plans to hold its first extraordinary shareholders' meeting of 2025 on June 16, 2025, to discuss the proposal [2]